Search results
Tolerizing vaccines for autoimmune diseases tempt BMS into $1.8bn collaboration
BioPharma-Reporter· 5 days agoBristol Myers Squibb (BMS) has bet up to $1.8bn in a collaboration with Repertoire Immune Medicines...
J&J, Bristol Myers lose challenges to US drug price negotiation program
KFGO· 5 days agoBy Brendan Pierson (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb...
After 'reset,' Flagship startup lands $1.8B Bristol Myers Squibb deal - Boston Business Journal
The Business Journals· 6 days agoTorben Straight Nissen took over the reins of Repertoire Immune Medicines at the tail end of 2022,...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to...
Morningstar· 6 days agoRepertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year ...
Repertoire partners with Bristol Myers for autoimmune vaccines By Investing.com
Investing.com· 6 days agoRepertoire Immune Medicines, a biotech firm specializing in T cell targeted immune therapies, has...
Pharma R&D productivity seen improving for the first time in years
Seeking Alpha· 6 hours agoDiscover the latest findings on the return on investment from pharmaceutical...
Judge rejects J&J, BMS challenges to Medicare drug pricing program
NJBIZ· 3 days agoA federal judge in New Jersey tossed lawsuits from Johnson & Johnson and Bristol Myers Squibb...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to...
CBS 47 Fresno· 6 days agoRepertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year ...
Insider Buying: BOERNER CHRISTOPHER S., Bristol-Myers Squibb Co. [BMY] Chief Executive Officer...
Knox Daily· 3 days agoThe buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Bristol-Myers Squibb Co. shares valued at $99,560 were purchased ...
Repertoire pivot pays dividends with Bristol Myers deal
BioPharma Dive via Yahoo Finance· 6 days agoThe alliance validates the new direction pursued by Repertoire, a startup that cut staff and...